Virtus Biotech ETF
BBP
17 hedge funds and large institutions have $9.8M invested in Virtus Biotech ETF in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4.11% less ownership
Funds ownership: 33.86% → 29.75% (-4.1%)
11% less funds holding
Funds holding: 19 → 17 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
74% less capital inflows, than outflows
Capital inflows: $933K | Capital outflows: $3.58M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$447K |
| 2 |
Morgan Stanley
New York
|
+$237K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$221K |
| 4 |
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$14.8K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.26M |
| 2 |
Virtu Financial
New York
|
-$1.23M |
| 3 |
Jane Street
New York
|
-$668K |
| 4 |
Private Advisor Group
Morristown,
New Jersey
|
-$288K |
| 5 |
LPL Financial
San Diego,
California
|
-$72.6K |
BBP Hedge Fund Activity: Q2 2018 in Review
17 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q2 2018, worth a combined $9.8M — down 18% from $11.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBP and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $447K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $1.26M sold.
- 17 institutional investors held Virtus Biotech ETF (BBP) as of Q2 2018, down from 19 in Q1 2018.
- Funds reported $9.8M of Virtus Biotech ETF stock for Q2 2018, down 18% quarter-over-quarter.
- 2 funds opened new Virtus Biotech ETF positions in Q2 2018 and 4 closed out, a net change of -2 holders.
- The largest Virtus Biotech ETF buyer in Q2 2018 was Citadel Advisors, an estimated $447K added.
- The largest Virtus Biotech ETF seller in Q2 2018 was Susquehanna International Group, an estimated $1.26M sold.
Based on aggregated 13F filings for Q2 2018.